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ABSTRACT 
The vesicular drug delivery systems are promising approaches to overthrown the problems of drugs having lesser bioavailability and rapid 
elimination from the body. The four type of lipid based drug delivery systems are: solid-lipid particulate system, emulsion based system, solid lipid 
tablet and vesicular system. Cryptosomes, a novel emerging vesicular drug delivery system which can overcome the disadvantages associated with 
conventional drug delivery systems like high stability, increased bioavailability, sustained release, decreased elimination of rapidly metabolizable 
drugs etc. The word Cryptosome was orginated from Greek word ‘’Crypto’’ means hidden and ‘’Soma’’ means body. It is formed from the mixture of 
phospholipids like distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG) with distearoylphosphatidylcholine. These entire 
information regarding its origin and formation is explained in Dinesh Kumar et al. Vesicular systems symbolizes the use of vesicles in the different 
fields as carrier system or additives. This review disclose various vesicular drug delivery system and point out the advancement of cryptosome in 
the world of drug delivery. 
This review would help researchers involved in the field of vesicular drug delivery. 
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In the present scenario of drug discovery systems, various drug 
delivery systems are introduced to enhance the therapeutic 
activity and to reduce the adverse effect of various new drugs, one 
such drug delivery system is Cryptosomes. It is a type of lipid 
based drug delivery system or liposome. Over the past three years 
the study of various liposomes are carried out in hope that they 
can be used for drug delivery in humans and animals [1, 2]. This 
system enabled a remarkable growth in drug discovery, 
development, and use. The lipid based drug delivery systems 
(LDDS) contain different group of formulations based on varying 
structural and functional characteristics by varying the 
composition of lipids and other additives. LDDS has advanced over 
time from micro to nano-scale by improving the efficacy and 
therapeutic application of this systems. The LDDS is classified into 
four types, including the solid lipid particulate dosage form, 
emulsion based system, solid lipid tablets and vesicular systems. 
The Cryptosomes is a type of vesicular drug delivery system.  
The vesicular system plays the central role in novel drug delivery 
(NDD), particularly in sorting of diseased cell, diagnostics, gene 
and genetic materials safe, effective and targeted in vivo drug 
delivery. They act as sustained release system and reduces 
elimination of rapidly metabolizable drugs. Over the past few 
decades they were widely used as drug carriers. The term 
Cryptosomes was derived from the Greek word Crypto means 
hidden and Soma means body or carrier. This lipid vesicle 
circulate in blood for long period of time after systemic 
applications and have decreased phagocyte mononuclear uptake 
[3, 4]. They have a surface coating formed by the assembly of 
phosphatidylcholine and polyoxyethylene, which are the 
derivatives of phosphatidylethanolamine. The Cryptosomes is 
formed from the mixture of phospholipids like distearoyl-
phosphatidylethanolamine-polyethylene glycol (DSPE-PEG) with 
distearoylphosphatidylcholine [5, 6]. Cryptosomes are also known 
as Immune-liposomes, as they can evade detection in an immune 
system. Properties of Cryptosomes may vary according to the way 
in which the polyethylene glycol (PEG) is linked to the lipid. [7, 8] 
Cryptosomes are long lived lipid vesicles and their longevity is 
explained on the basis of rigidity of phospholipid bilayer, surface 
hydrophilicity, which are essential to keep this vesicle in the blood 
circulation [9-11]. Another main factor affecting longevity of 
Cryptosomes circulation in vivo is the suppression of adsorption of 
macromolecules on to the surface of such vesicle. This adsorption 
can be prevented by mobile steric hindrances near the lipid 
surface.  
There are different type of vesicular drug delivery systems [12] like 
enzymosome, virosome, ufasome, cryptosome, emulsosomes, 
discosomes, aquasomes, genosomes, ethosomes, archaeosomes, 
hemosomes, vesosome, proteosome, erythrosomes, photosome, 
cubosome, collidosome, layerosome, erythrosome etc. The complete 
information regarding the various types of vesicular drug delivery 
systems and their applications are explained in Biju SS et al. and 
Priyanka Rathore et al. 
Composition of cryptosome  
Cryptosomes are liposomal composition which comprises of 
poloxamer molecules (polymers) and liposomes embedded with 
one or more delivery agents. The poloxamer is also termed as 
pluronics. The generally used poloxamers are Polyethylene Oxide 
(PEO), Polypropylene Oxide (PPO), PEO-triblocks co-polymers of 
varying molecular weights (fig. 1). The hydrophobic 
Polypropyleneoxide groups at the centre is bonded with two 
hydrophilic polyethylene oxide groups. The polymers of 
hydrophilic PEO groups on each side of the PPO units can provide 
steric hindrance and thus protection to the bilayer surface. This 
nature make them useful as emulsifiers and stabilizers. The 
liposomes are made up of various lipids, it include either 
phospholipids (fig. 2) like phosphatidylcholine, 
phosphatidylserine, phosphatidylglycerol, phosphatidyl-ethanol-
amine, phosphatidylinositol, or the other lipids like sphingolipids, 
glycolipids, fatty acid, and cholesterol at various proportions [31].  
The phospholipid based drug delivery system has provided the 
evidence of increased pharmacokinetic and pharmacodynamics 
activity of drug compared to conventional one [32]. 
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Table 1: Types of vesicular drug delivery systems 
Vesicular 
systems 
Characterization Application Reference 
Enzymosome 
 
The liposomes that are generated to act as a bio-environment, in 
which the enzymes are covalently bound to their surface. 
It is used in tumour for targeted drug 
delivery. 
[13] 
Virosomes Liposomes with viral glycoprotein embedded to the liposomal 
bilayer 
They are used in ligand-mediated drug 
delivery system and immunological 
products. It is used in the influenza vaccine. 
[14] 
Ufasomes Liposomes embedded with fatty acid obtained from long chain fatty 
acid like oleic acid or linolenic acid. They have better penetration 
through skin layers.  
They are used in targeted drug delivery 
system. It exhibit high stability, enhanced 
drug entrapment. 
[15] 
Cryptosomes Liposomes with surface coat formed by PC and polyoxyethylene 
which are the derivatives of phosphatidylethanolamine. 
They act as efficient ligand-mediated drug 
delivery system. 
 
Emulsosomes A polar core with microscopic assembly of lipids having nanosized 
particle. 
It is used in the parenteral administration 
of hydrophilic drug moiety.  
[16] 
Discosomes Non-ionic surfactant hydrolysed solubilised niosome. It act as a ligand-mediated drug delivery 
system. Used as an ophthalmic drug carrier. 
[17] 
Aquasomes Nanocrystalline particulate core coated with an oligomeric film. They act as an efficient targeted drug 
delivery system. In gene and antigen 
delivery it is used. They maintain 
conformation and enhance drug stability. 
[18, 19] 
Genosomes They are synthetic macromolecular complexes for gene transfer. 
Usually, positively charged lipids are used as they exhibit increased 
biodegradability and stability in blood  
They are used in cell specific gene transfer. [20] 
Ethosomes They are lipid malleable vesicle embedding permeation enhancer 
formed by phospholipid, ethanol and water. 
They are used in targeted drug delivery to 
the skin. 
[21] 
Archaeosomes They contain glycerolipids of archaeabacteria membrane. And 
having very high potent activity 
Enhanced stability on varying conditions of 
temperature, pressure and pH. 
[22] 
Hemosomes They are liposome containing haemoglobin used by immobilizing 
with phospholipids which are polymerisable. 
They are having very high oxygen carrying 
property. 
[23] 
Vesosome They have interdigitated bilayer phase formed by incorporating 
ethanol to different type of saturated phospholipids. 
The multiple compartments of vesosome is 
highly beneficial for protection of internal 
contents.  
[24] 
Proteosome They have subunits of enzymes with high molecular weight 
complexed with particular catalytic activity which is specifically 
due to the difference in the arrangement pattern of enzymes. 
They exhibit higher catalytic activity. [25] 
Erythrosomes They are liposome in which cross-linked human red blood cells or 
erythrocytes cytoskeletons used as a support 
They are used in targeted drug delivery of 
macromolecular drugs. 
[26] 
Photosome Liposome incorporated with photolyase enzyme which deliver the 
compound by photo-triggered charges in the membrane. 
They are used in photodynamic therapy. [27] 
Cubosome They are bicontinuous cubic phases, composed of two separate 
continuous phases. And the non-intersecting hydrophilic regions 
are separated by a lipid layer. 
Targeted drug delivery. [28] 
Collidosome The self-orientation of colloidal particles at the interface of 
emulsion droplet result in the formation of solid microcapsules. The 
collidosomes are elastic and hollow in nature, whose permeability 
and elasticity can be varied.  
Targeted drug delivery.  
Layerosome Multi-layered liposome, with each layer consisting of biocompatible 
electrolytes to increase the structural stability. 
Potential for oral use of administration. [29] 
Erythrosome It consist of an erythrocyte cytoskeleton with lipid bilayer 
membrane. 
It is used as an entrapment system for 




Fig. 1: Types of poloxamers 
Source of figure: Science direct article Reference no: 28 
Nair et al. 




Fig. 2: Types of phospholipid involved are 
Source of figure: science direct article Reference no 28 
 
Lipid core 
It is composed of lipids. They are naturally occurring substances like 
fat, wax, sterols and the fat-soluble vitamins [like A, D, E and K]. 
Lipids are widely used in immunology, membrane biology and 
diagnostic purposes. Either one or more lipids can be used for the 
synthesis of lipid core. The lipids are generally hydrophobic in 
nature and are determined by the concentration of fatty acid, 
melting point, hydrophilic-lipophilic balance (HLB). For sustained 
release of drugs, lipids with lower HLB and increasing melting point 
are used. The lipids with higher HLB cause rapid drug release and 
increased bioavailability [33-36].  
Phosphatidylcholine 
Lecithin is mainly composed of the phosphatidylcholine. Its 
solubility in water is very less. Based on temperature and hydration, 
phospholipid in aqueous medium forms bilayer sheets, micelles, or 
lamellar structure. This kind of surfactants are classified into 
amphipathic type. It forms the important constituent of biological 
membranes like egg yolk or soya bean. Based on the origin from 
which they are derived they are known to be as egg lecithin and soya 
lecithin. By the introduction of lecithin the drug entrapment to the 
vesicle also increases to a great extent [37, 38]. 
Cholesterol 
The cholesterol form an important constituent of a vesicles. The 
introduction of cholesterol increases the stability of vesicle to a 
great extent [39, 40]. The composition of cholesterol influence the 
drug entrapment in vesicle [41]. As the concentration of cholesterol 
increases drug entrapment ability of vesicle also increases. But if the 
concentration of cholesterol is very high the entrapment efficiency 
decreases to a great extent. This is because of the fact that after a 
particular level cholesterol cause disturbances in the bilayer and 
thereby reducing the drug entrapment [42]. 
Negatively charged particles 
The phosphatidylinositol is a type of negatively charged 
phospholipid. The incorporation of negatively charged particle 
decreases the aggregation of particles and it also reduces the 
coalescence, flocculation or fusion [43]. 
Surfactants 
Surfactants are selected based on (HLB). It act as indicator of ability 
of a surfactant to form a vesicle. HLB of range 4-8 are suitable for 
vesicle formation [44]. The variation in temperature of surfactant 
influence the entrapment of drug in to the vesicle. The spans which 
are having highest phase transition temperature exhibit increased 
drug entrapment [45, 46]. The high phase transition temperature 
and less permeability cause leaching of drug from the lipid vesicle 
[47]. High HLB value of span 40 and 60 cause decrease in surface 
free energy which results in vesicles of larger size and thereby 
increasing the area exposed to the dissolution medium [48-51]. 
Formulation of cryptosome 
Cryptosomes are formed from liposomes and poloxamer molecules. 
Above the critical micellar temperature the polaxamer molecules 
form micelles, and a fraction of them get introduced into the surface 
of liposome thus preventing their adhesion to the cells. Polaxamer 
molecules dissociate below their critical micellar temperature to 
form monomers, permitting the liposome to adhere to the 
neighbouring cells and influence the holding of liposome on the 
adjacent cells. The targeted release of agents involves the 
introduction of components into the monomers and cooling the 
target site, which confines the liposomes at or near the targeted site. 
The liposomes are prepared by the various method. The lipid 
vesicles can be prepared by standard techniques like sonication and 
extrusion. They can also be synthesised from reversed phase 
evaporation, detergent dialysis and freeze–thawing. After various 
steps involved in the synthesis of liposome (fig. 3) the polaxamer 
molecules are incorporated into it to form the Cryptosomes. 
The liposomes collected is treated with poloxamer molecules and get 
embedded in it. The stealthing of liposome is primarily done by using 
polyethylene glycol and poloxamer or polymer. This results in the 
formation of Cryptosomes. The complete information regarding the 
formulation is explained in Mayank Gangwar et al. The PEG of 
molecular weight in the range of 1000 to 5000 exhibit prolonged 
circulation and decreased uptake by mononuclear phagocytic system 
(MPS) [52]. The most commonly used phospholipid in the formulation 
is phosphatidylcholine, it form the elementary unit of plasma 
membrane, it act as a safeguard of polyphenolics, and it also exhibit 
both hydrophilic and lipophilic analogs, the phosphatidyl moiety being 
lipophilic and choline moiety being hydrophilic nature [53]. 
Methods of formulation 
Sonication method  
To a round bottom flask varying molar ratios of 
phosphatidylcholine, cholesterol, lipids were taken and dissolved in 
chloroform having 3-4 drops of methanol. The proper amount of 
drug was weighed and added to that. Then evaporated the organic 
layer until dry in the presence of rotary evaporator in a reduced 
Nair et al. 
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pressure condition. This result in the formation of a lipid film on sides of round bottom container [54, 55]. 
  
 
Fig. 3: The steps involved in the synthesis of liposome as follows 
Source of figure: science direct article Reference no 28 
 
Detergent removal technique  
Miceller mixture is formed by mixing the phospholipid and 
detergent. Then the detergent is removed from the mixture by 
adsorption or column chromatographic technique. The phospholipid 
contents in the micelles increase and lipids come closer to form a 
vesicle of single bilayer [56]. 
Reversed phase evaporation  
It consist of two step. By using phospholipid and buffer, a water in 
oil type of emulsion is prepared. Then under reduced pressure 
organic layer is separated and removed. Both water and 
phospholipid layer is emulsified my sonication or by other 
mechanical methods. Due to the removal of organic layer in 
vaccum condition, a gel like matrix is formed, as the phospholipid 
coated water droplets comes closer. A paste of smooth texture is 
formed on further loss of organic phase under vaccum. This paste 
form the suspension of LUVs [57]. The efficiency of incorporation 
of drug can be achieved upto 60-65% by this method. Therefore it 
can be used for incorporation of both small and large molecules 
[58]. 
The information regarding the structure is from Biju SS et al. The 
structure of cryptosome is given below (fig. 4). 
 
 
Fig. 4: Structure of cryptosome 
Source of figure: Reference no 12 
Nair et al. 
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Drug release from cryptosomes 
The phospholipid bilayer of Cryptosomes fuse with other bilayer 
membranes (e. g. cell membrane) and thus releasing the liposomal 
contents. This takes place either by endocytosis or adsorption to the 
cell surface. In endocytosis, the lipid bilayer fuses with the plasma 
membrane and releasing the contents. But in the case of adsorption 
to the cell surface, transfer of liposomal contents takes place. 
 
Table 2: Cryptosomes V/S ordinary liposome [59] 
Cryptosomes Ordinary liposome 
They are sterically well stabilized They are not sterically well stabilized as compared to Cryptosomes. 
It is used for targeted drug delivery. It is not efficiently used for targeted drug delivery. 
It exhibits Reduced recognition and uptake by macrophages It exhibit enhanced recognition and uptake by macrophages 
Prolonged circulation and half-life. Reduced circulation and half-life. 
It is efficiently used in dose-independent pharmacokinetics. It may be efficiently used in dose-independent pharmacokinetics. 
It exhibit increased uptake in vivo by solid tumors and breast cancer. It exhibits reduced uptake in vivo by solid tumours and breast cancer. 
Decreased tendency to leak the drug during blood circulation. Increased tendency to leak the drug during blood circulation. 
 
Uses and applications of cryptosome 
 Cryptosome can be used as potential carriers of biologically 
active compounds. 
 Polyethylene glycols (PEG)-coated long-circulating sustained 
release liposomes, exhibit improved efficacy of ciprofloxacin 
administered for the treatment of Klebsiella-pneumoniae causing 
pneumonia [60].  
 Doxil the liposomal formulation of doxorubicin containing 
polyethylene-glycols shows increased therapeutic activity, prolonged 
circulation time, and accumulation time in murine tumors over free 
(unencapsulated) doxorubicin (DOX). Liposome longevity in malignant 
effusions is related to improved drug accumulations [61]. 
 It can be used for slow release of drug, tumour imaging and 
therapy [62, 63]. 
 It is enhanced the drug delivery in solid tumours [64, 65] and 
breast cancer [66-71]. 




Fig. 5: Ligand mediated drug delivery system 
Source of figure: Reference no 72 
 
CONCLUSION 
One of the greatest challenge faced by the scientist is to improve the 
dosage forms for increasing their half-life or duration of action. 
Cryptosome, due to high stability, prolonged circulation, increased 
half-life, reduced recognition and uptake by macrophages, are 
considered as one of the most efficient vesicular drug delivery 
systems. This is a lipid vesicle with surface coat, circulate in the 
blood for a long period of time after systemic applications. This 
system enabled a remarkable growth in drug discovery, 
development, and use. They have attained a huge engrossment 
among different novel vesicular drug delivery systems with a 
phospholipid bilayer and a lipid core. Vesicular systems symbolises 
the use of vesicles in the different fields as a carrier system or 
additives. It is used as a potential carrier of biologically active 
compounds. It is found applicable in the field of tumour imaging and 
therapy. In future in association with other strategies, Cryptosome 
like vesicle will play the central role in novel drug delivery in 
diagnosis and targeted drug delivery. 
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